Background
Multiple sclerosis is a chronic autoimmune disease that damages the central nervous system through inflammation, loss of myelin, and progressive neurodegeneration. Its prevalence has been increasing worldwide, with variations that reflect genetic predisposition, environmental influences, and immune system dysregulation.
Main Body
Advances in high-resolution magnetic resonance imaging and the use of cerebrospinal fluid biomarkers have enhanced the ability to detect early disease activity, monitor progression, and evaluate therapeutic response. Despite these improvements, challenges remain in understanding the mechanisms driving disease progression, particularly in progressive forms of multiple sclerosis where treatment options are limited. Barriers such as unequal access to therapies, variable long-term efficacy, and incomplete knowledge of disease pathways continue to hinder effective management. Current research emphasizes the need for personalized approaches that incorporate genetic, immunological, and environmental factors. Efforts are also being directed toward identifying neuroprotective and remyelinating agents, alongside integrating biomarkers into treatment strategies, in order to better tailor therapies and improve monitoring of disease activity.
Conclusion
Future directions in multiple sclerosis research should focus on precision medicine, the discovery of novel therapeutic targets, and the integration of biomarkers into clinical care. These strategies hold the potential to improve long-term outcomes, reduce disease burden, and enhance the quality of life for affected individuals. This review explores global epidemiological patterns, recent diagnostic innovations, and the effectiveness of emerging treatment strategies in multiple sclerosis.
扫码关注我们
求助内容:
应助结果提醒方式:
